Free Newsletter
ALSO NOTED: Genetic test for warfarin sensitivity OK'd; Bayer boosts OTC production
> The FDA also cleared a new genetic test to determine over-sensitivity to the blood thinner warfarin, a month after updating drug labeling to alert doctors that patients carrying certain genes respond differently. Release
> Bayer is ramping up its production of OTC drugs at its Bitterfield, Germany, manufacturing plant, aiming to boost output to 6 million pills this year, up from 4.1 million in 2006. Report
And Finally... We're used to news that antibiotics can spawn resistant superbugs. But a vaccine? Apparently, Wyeth's super-successful Prevnar shot has successfully prevented pneumonia, meningitis, and other infections, but it's also cleared the way for a new, resistant strain of strep. Report
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline


SHARE
WITH: